

INTERNATIONAL WORKSHOP ON **PEDIATRICS**

2021



VIRTUAL WORKSHOP
16 - 17 JULY



Program



Dear Colleagues,

We are happy to welcome you to the **13th International Workshop on HIV Pediatrics 2021!** While we had hoped to see all of you in person, given the continued SARS-CoV-2 global pandemic and the still-limited COVID-19 vaccine implementation, the Workshop is being held virtually again this year. One advantage of the virtual platform is that it allows more individuals from around the world to participate and connect virtually, with 389 individuals from 49 countries participating in the Workshop in 2020.

As always, the Workshop will showcase the latest developments in pediatric and maternal HIV research in an innovative and interactive global platform and in a variety of formats that will be accessible throughout the meeting, including:

- **Plenary talks** from top experts in perinatal/pediatric/adolescent HIV research that cover a range of topics:
 - Latest 2021 UNAIDS data on pediatric HIV, including effects of the COVID-19 pandemic on HIV parameters in 2020, and an update from the WHO on what is new in pediatric HIV treatment and prevention and new recommendations from 2021 WHO guidelines;
 - Possibilities and challenges of the new long-acting HIV prevention modalities for adolescents, including cabotegravir-LA (shown to be more effective than oral TDF/FTC in the HPTN 083/084 trials) and other modalities under study such as broadly neutralizing antibody and new long-acting drugs such as islatravir and lenacapavir;
 - New approaches to enhance and accelerate study of new drugs for HIV and coinfections in pregnancy, reflections from the WHO/IMPAACT ARV in Pregnancy workshop discussions over the past year;
 - Review of what we know about the COVID-19 pandemic in African children; and
 - Progress- and lack of progress – on dolutegravir transition in children.
- Interactive **clinical case presentations** on critical issues in pediatric HIV infection with an international panel of discussants.
- Concurrent **oral abstract sessions** that will highlight the latest advances in pediatric and adolescent HIV treatment and care, including the latest data from clinical trials; complications of maternal or pediatric ART; global impact of COVID-19 on pediatric and adolescent HIV programs; prevention of perinatal transmission; and effects of HIV in pregnancy.
- Four concurrent **“poster walk” sessions** highlighting the top posters from young investigators moderated by experts in pediatric and perinatal HIV research.
- An **entertaining and educational debate** pro and con “Children should be prioritized for COVID-19 vaccine”.
- Over 50 **e-posters** on the latest in pediatric, adolescent, and maternal HIV research with short video presentations, available “on demand”.
- A **lunch-time symposium** from ViiV on “Optimizing care in pediatric HIV treatment”.
- An “on demand” special **adolescent panel** of youth from around the world discussing their perceptions about long-acting HIV prevention modalities moderated by Dr. Caroline Foster from Imperial College in London.
- A **“Young Investigator Meet the Faculty”** breakfast session to allow dialogue of young investigators with members of the Pediatric Workshop Organizing Committee.



Elaine Abrams, MD

ICAP Mailman School of Public Health, Columbia University, United States

Workshop Chair



Lynne Mofenson, MD

Elizabeth Glaser Paediatric AIDS Foundation, United States

Workshop Chair



The Workshop in 2021 is dedicated to Dr. Charles Boucher, co-founder and Scientific Director at Virology Education, who sadly passed away this year after a courageous battle with cancer. The International Pediatric HIV Workshop was initially the conception of Dr. Boucher, developed in concert with the Workshop Scientific Committee, with the first Workshop in 2009 in Cape Town, and we have worked closely with him since then. We want to honor Dr. Boucher's work as an "honorary pediatrician" and for his origination of this Workshop.



We are excited to have you join us to share the latest advances in clinical and prevention research in pediatric HIV and its intersection of the COVID-19 pandemic in this virtual format – and hope you will also join us in person at the **July 27 and 28, 2022 meeting in Montreal, Canada** being held just prior to the 2022 IAS Conference.

Lynne Mofenson, Elaine Abrams, and the HIV Pediatrics Organizing Committee and Workshop Team



Meeting & Learning Objectives

Meeting Objectives

The meeting aims at:

- Enhancing communication and encouraging new collaborations between junior and senior investigators, north and south, and academia, governmental public health agencies, and industry to promote advances in HIV prevention and care in children, youth and families.
- Disseminating knowledge and data exchanged by workshop participants beyond the audience of the live event through posting of all presentations on the meeting website, thus maximizing the impact of the meeting by reaching the whole HIV research community.
- Providing updates on the latest research on new pediatric antiretroviral drugs and treatment and prevention strategies in children and adolescents.
- Understanding new long-acting prevention technologies and their application for prevention of HIV in adolescents.
- Evaluating effectiveness of and gaps in programs for prevention of perinatal HIV transmission and interventions to improve such programs.
- Sharing results from implementation science research on how to optimally implement proven interventions for prevention of perinatal HIV transmission and for pediatric and adolescent care and treatment in developing countries.
- Understanding complications of long-term HIV infection and its therapy, to enable improved management of HIV in children and adolescents.

Learning Objectives

After attending this Workshop the participant will be able to:

- Describe the changing epidemiology of the pediatric HIV epidemic world-wide and the latest recommendations for pediatric and adolescent HIV treatment.
- Describe the impact of the COVID-19 pandemic on pediatric and maternal HIV programs and what we know about SARS-CoV-2 infection in African children.
- Summarize optimal treatment and management strategies of HIV infection in infants, children, adolescents, and pregnant and postpartum women.
- Describe potential complications of HIV and newer HIV treatments on children, adolescents, and pregnant/postpartum women.
- Summarize strategies to improve perinatal HIV prevention programs and to better understand continued risk for perinatal transmission in the ART era.
- Describe special issues related to HIV infection in adolescents and young people and new HIV prevention modalities and programming options for youth.



Abstracts

Accepted abstracts are published in Reviews in **Antiviral Therapy & Infectious Diseases, Volume 2021_5**.

Certificate of attendance

Certificates of attendance will be sent by e-mail after completion of the feedback forms.

Feedback

Your feedback is very valuable to us and enables us to further improve this workshop. After each session a short questionnaire will pop-up and we would like to ask you to take a minute to complete it. After the workshop, a survey will be sent to you via email, with other questions to improve this workshop

Group picture

We ask you all to take a photo of yourself watching the workshop and send it to the workshop secretariat at lara@amededu.com or karin@amededu.com. They will stitch it all together and send out the finished virtual group photo at the end of the workshop.

Networking

The Meeting Hub allows you to connect and communicate with other attendees. Once you have located an attendee you want to connect with, click the Connect button. Once the other attendee accepts your request, you can choose to interact by starting a live chat or live video call. You can also schedule a meeting at a later time, send messages and take notes. Contact information for all attendees you have connected with will be included when you export contacts.

Notes

You will be able to take notes during the virtual workshop. Any notes that you take throughout the event can be exported by selecting the Export icon

in the top right of the screen near your Profile image.

OnAIR

OnAIR is the virtual meeting platform being used for HIV Pediatrics 2021. A video tutorial on how to use the Workshop Portal can be found [here](#)

Social Media

We encourage you to post news about **#HIVPED** to your social media accounts and tweet about **#HIVPED** as often as you like during the workshop. You can either post your own tweet to your followers using the hashtag **#HIVPED** or retweet a message through the official [@Virology_Edu](#) account.

Poster sessions

During the virtual workshop all accepted posters are displayed in the Poster Gallery. The Poster Gallery is always open for you.

During the Virtual Break on Monday at 12.15 PM you can visit the posters and interact with the presenters - just like if it was a face-to-face workshop. Please make sure to make use of this opportunity and learn more about their interesting findings.

Presentations and webcasts

ame Webcasts of the presentations along with the PDF presentations will be available on www.AcademicMedicalEducation.com 3 weeks after the meeting. You will be able to watch the presentations on the workshop portal until 3 weeks after the workshop

Time Zones

Times are in Eastern Daylight Time. If you need to convert the times to your timezone, this website might be of interest to you: <https://www.worldtimebuddy.com/>

Our Team



Karin Siebelt
Senior Project Manager
karin@amededu.com



Lara da Silva Miguel
Project Coordinator
lara@amededu.com

Disclaimer: This workshop aims to offer participants the opportunity to share information. The Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaim all liability for injuries or losses of whatever nature incurred by individuals attending the conference.



“The International Workshop on HIV Pediatrics, Virtual, Netherlands, 16/07/2021-17/07/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **5 European CME credits (ECMEC®s)**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.”

“Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

“Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.”



Organizing Committee



**Elaine Abrams,
MD**
ICAP Mailman School of Public
Health, Columbia University,
United States



**Charles Boucher,
MD, PhD**
Erasmus Medical Center, The
Netherlands



**Mark Cotton,
MD, PhD**
Stellenbosch University,
South Africa



**Patricia Flynn,
MD**
St Jude Children's Research
Hospital, United States



**Carlo Giaquinto,
MD**
PENTA, / University of Padova,
Italy



**Lynne Mofenson,
MD**
Elizabeth Glaser Paediatric
AIDS Foundation, United States



**Thanyawee Puthanakit,
MD**
Chulalongkorn University,
Thailand



**Nadia A. Sam-Agudu,
MD, CTropMed**
University of Maryland School
of Medicine / Institute of
Human Virology, United States
/ Nigeria



**Gareth Tudor-Williams,
MD**
Imperial College London,
United Kingdom



Scientific Committee

- Moherndran Archary, MBChB, DOH, FCPaedS**, University of KwaZulu Natal, South Africa
- Jason Brophy, MD** - Children's Hospital of Eastern Ontario, Canada
- Ellen Chadwick, MD** - Childrens Memorial Hospital, United States
- Tsungai Chipato, MBChB** - University of Zimbabwe College of Health Sciences, Zimbabwe
- Polly Clayden** - HIV i-Base, United Kingdom
- Anita De Rossi, PhD** - AIDS Reference Center, Italy
- Marinella Della Negra, MD** - Hospital Emílio Ribas, Brazil
- Brian Eley, MD** - Red Cross Children's Hospital, Department of Pediatrics, South Africa
- Albert Faye, PhD** - Denis Diderot University, Paris, France
- Rashida Ferrand, MBBS, MRCP, MSc, DRM&H** - London School of Hygiene & Tropical Medicine, United Kingdom
- Tessa Goetghebuer, MD** - Hôpital St Pierre, Belgium
- Ali Judd, PhD**, London School of Hygiene and Tropical Medicine, United Kingdom
- Valériane Leroy, MD** - Inserm, Paris, France
- Chewe Luo, MD, PhD** - UNICEF, United States
- Dorothy Mbori-Ngacha, MBChB, MMed, MPH** - United Nations Children's Fund, South Africa
- Sharon Nachman, MD** - SUNY Stony Brook / IMPAACT Network, United States
- Paul Palumbo, MD** - Dartmouth-Hitchcock Medical Center, United States
- Martina Penazzato, MD, MSc, PhD** - WHO, Switzerland
- Ann Petru, MD** - UCSF Benioff Children's Hospital Oakland, United States
- Jorge Pinto, MD, DSc** - School of Medicine, Federal University of Minas Gerais, Brazil
- Natella Rakhmanina, MD, PhD, FAAP, AAHIV** - Children's National Medical Center / EGPAF, United States
- Theodore Ruel, MD** - UCSF Benioff Children's Hospital San Francisco, United States
- George Siberry, MD, MPH** - United States Agency for International Development (USAID), United States
- Lynda Stranix-Chibanda, MBChB, MMED** - University of Zimbabwe, Zimbabwe
- Tavitiya Sudjaritruk, MD, ScM, PhD** - Chiang Mai University, Thailand
- Graham Taylor, MD** - Imperial College London, United Kingdom
- Claire Thorne, BA, MSc, PhD** - University College London, United Kingdom
- Marissa Vicari** - International AIDS Society, Switzerland
- Rachel Vreeman, MD, MS** - Icahn School of Medicine at Mount Sinai, United States



Friday, 16 July 2021

Times are in Eastern Daylight Time (EDT)

On Demand Youth Panel

Chair: *Caroline Foster*

MUST WATCH - Adolescents in conversation with Dr. Caroline Foster talking about PrEP – including long-acting injectables

Saidy Brown

South Africa

Tony Ramirez

United States

Xavier Ramos

United States

Munkh-Erdene Davaajav

Mongolia

Opening of the Workshop

10:00 AM **Opening Words**

Lynne Mofenson, MD

Elizabeth Glaser Pediatric AIDS Foundation, United States

Elaine Abrams, MD

ICAP at Columbia University, United States

Session 1 Global Updates

Chair: *Elaine Abrams*

10:10 AM **The HIV Epidemic in Infants, Children, Adolescents, and Women Today
2021 UNAIDS Update**

Mary Mahy, ScD, MHSc

UNAIDS, Switzerland

10:27 AM **Pediatric HIV Treatment and Prevention: What's New for 2021**

Martina Penazzato, MD, MSc, PhD

WHO, Switzerland

10:45 AM **Discussion**

11:05 AM Virtual Coffee Break - Time to Network

Session 2 Oral Abstract Presentations - 3 Parallel Sessions

Pediatric Treatment

Chair: *Moherndran Archary*

11:15 AM	Once-Daily Integrase Inhibitor (Insti) With Boosted Darunavir is Non-Inferior to Standard of Care in Virologically Suppressed Children, Week 48 Results of the Smile PENTA-17 Trial	Alexandra Compagnucci, France	#1
11:23 AM	B/F/Taf in Virologically Suppressed Adolescents and Children: Two-Year Outcomes in 6 to <18 Year Olds and Six-Month Outcomes in Toddlers	Eva Natukunda, Uganda	#2
11:31 AM	Pharmacokinetics and Safety of Dispersible- and Immediate-Release FDC Dolutegravir/Abacavir/Lamivudine in Children with HIV Weighing ≥14 Kg: Preliminary Results from IMPAACT 2019	Kristina Brooks, United States	#3
11:39 AM	Long-Term Safety & Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate (E/C/F/TAF) Single-Tablet Regimen in Children and Adolescents Living With HIV	Suvaporn Anugulruengkitt, Thailand	#4
11:47 AM	Pharmacokinetics, Safety and Acceptability of a Single Dose of Abacavir/Lamivudine/Lopinavir/Ritonavir (4-In-1) Fixed-Dose Granule Formulation In Neonates: PETITE Study	Tim Cressey, Thailand	#5



11:55 AM	Clinical Impact and Cost-Effectiveness of Viral Load Testing (VLT) to Inform the Transition to Pediatric Dolutegravir (DTG) in Antiretroviral Therapy (ART)-Experienced Children With HIV in South Africa	Isaac Ravi Brenner, United States	#6
12:03 PM	LATE BREAKER - Dolutegravir-Based Art is Superior to Standard of Care in Young Children Living With HIV	Pauline Amuge, Uganda	#124
12:11 PM	Q & A		
Complications of Pediatric or Maternal ART <i>Chair: George Siberry</i>			
11:15 AM	Weight Gain in Children and Adolescents on Dolutegravir vs Standard-of-Care in the ODYSSEY Trial	Hilda Angela Mujuru, Zimbabwe	#7
11:23 AM	Dolutegravir and Weight Gain to Adolescents Living with HIV at Baylor Mwanza-Tanzania	Esther Masunga, Tanzania	#8
11:31 AM	Longitudinal Study on Insulin Resistance and Metabolic Syndrome in Children with Perinatal HIV Infection and HIV Exposed Uninfected Children in South Africa	Claire Davies, South Africa	#9
11:39 AM	Virological Failures and Genotypic Resistance in Children and Adolescents Randomised to Dolutegravir-Based ART vs. Standard-of-Care in the ODYSSEY Trial	Cissy Kityo, Uganda	#10
11:47 AM	Hypertensive Disorders in Pregnancy and HIV: A Province-Wide Cohort Analysis During 2018 and 2019 in the Western Cape, South Africa	Amy Slogrove, South Africa	#11
11:55 AM	Bone Mineral Density/Content of Postpartum Mothers Taking Treatment Including DTG Vs EFV, TDF vs TAF in Pregnancy and Their Infants: Randomized IMPAACT 2010 Trial	Tapiwa Mbengeranwa, Zimbabwe	#12
12:03 PM	Q & A		
Impact of COVID-19 Pandemic on Pediatric HIV <i>Chair: Lynda Stranix-Chibanda</i>			
11:15 AM	Impact of the COVID-19 Pandemic on Perinatal HIV Prevention in Canada: Canadian Perinatal HIV Surveillance Program	Joel Singer, Canada	#13
11:23 AM	A Comparative Multi-Country Analysis of the Impact of COVID-19 on HIV Services for Pregnant and Breastfeeding Women and Their Infants	Alexandra Vrazo, United States	#14
11:31 AM	Early Infant Diagnosis of HIV and Linkage to Antiretroviral Therapy in the Context of COVID-19 in Fifteen Sub-Saharan African Countries	Elizabeth Rabold, United States	#15
11:39 AM	The Impact of COVID-19 on HIV Services for Children Living with HIV Across 14 Countries	Megan Gleason, United States	#16
11:47 AM	Pediatric and Adolescent HIV Viral Load Coverage and Suppression Rates in the Context of the COVID-19 Pandemic in 14 Sub-Saharan African PEPFAR Countries in 2019 and 2020	Deborah Carpenter, United States	#17
11:55 AM	Knowledge and Perceptions of Covid-19 Among Young People Living With HIV in Malawi and the Impact of the Pandemic on Their Health and Wellbeing	Kajal Hirani, Malawi	#18
12:03 PM	Q & A		
12:15 PM	Virtual Lunch Break - Poster Viewing Session		



Session 3 Clinical Case Presentations

Chair: Gareth Tudor-Williams

12:45 PM **Case 1**
Katie Simon, MD
Baylor Children's Clinical Centre of Excellence, Malawi

1:10 PM **Case 2**
Katherine Hsu, MD, MPH, FAAP
Boston University Medical Center, United States

Commenters on Cases

Nadia Sam-Agudu, MD, CTROPED

University of Maryland School of Medicine / Institute of Human Virology Nigeria, United States / Nigeria

Thanyawee Puthanakit, MD

Chulalongkorn University, Thailand

Sharon Nachman, MD

SUNY Stony Brook / IMPAACT Network, United States

1:35 PM Virtual Coffee Break - Time to Network

Session 4 Guided Poster Tours - 4 Parallel Sessions

1:50 PM Guided Poster Tour 1 - Prevention of Perinatal HIV Transmission

Chair: Jason Brophy

Strategies Used in Countries With Successful Mother-Infant Pair Tracking	Aimee Rurangwa, United States	#37
Participatory PMTCT: Community Engagement For Co-Created PMTCT Programming in 2 Districts of Zimbabwe	Electa Mutyambizi, Zimbabwe	#38
Population-Level Risk Factors For Vertical Transmission of HIV Within the National Prevention of Mother-To-Child Transmission Programme in South Africa: An Ecological Analysis	Faith Moyo, South Africa	#39
Risk Factors For Adverse Pregnancy Outcomes Among Pregnancy Women Living With HIV on ART	Wenwen Jiang, United States	#40
Barriers to Early Infant Diagnosis (EID) at Different Stages of Infancy	Linda Ndlovu, South Africa	#41

1:50 PM Guided Poster Tour 2 - Pregnancy and HIV

Chair: Claire Thorne

Pregnancy Characteristics and Outcomes Among Migrant Women Living With HIV Recently Arrived in the UK	Rowan Eastabrook, United Kingdom	#42
Factors Associated With Recent HIV Infection Among Pregnant Women in Lilongwe, Malawi: A Case Control Study	Hanna Huffstetler, United States	#43
Prevalence of Depression Among Postpartum Women on Isoniazid-Preventive Therapy and Efavirenz-Based Treatment For HIV—An Exploratory Objective of the IMPAACT P1078 Randomized Trial	Patricia Mandima, Zimbabwe	#44
Trends in Characteristics and Care Of Women Diagnosed With HIV During Pregnancy in the UK	Rebecca Sconza, United Kingdom	#45
Feasibility and Acceptability of Administering the Cross Culturally Adapted ACTG Adherence Questionnaire to Ugandan Women Living With HIV Via Audio Computer Assisted Self Interview (ACASI) vs Via Provider-Assisted Interview	Patience Atuhaire, Uganda	#46

**1:50 PM Guided Poster Tour 3 - Pediatric Treatment and Care***Chair: Mark Cotton*

Behavioural and Emotional Outcomes at 7 and 9 Years in Children From the Children With HIV Early Antiretroviral (CHER) Trial: A Longitudinal Investigation	Kaylee van Wyhe, South Africa	#47
An Assessment of Multi-Month Dispensing of Antiretroviral Therapy For Children and Adolescents Across 10 African Countries	Ashley Sorgi, United States	#48
A Systematic Review and Meta-Analysis of HIV Risk Screening Tools to Identify At-Risk Children and Adolescents For HIV Testing	Nimasha Fernando, United States	#49
Effect of HIV on the Distribution of NK Cell Subsets and Their Phenotype in Infants Pre-ART Initiation and at 10 Months of Age	Vinh Dinh, United States	#51
Impact of COVID-19 on Ugandan Children with and Without HIV	Mina Milad, United States	#52

1:50 PM Guided Poster Tour 4 - Adolescents and HIV*Chair: Annette Sohn*

IMARA SA: Piloting A Family-Based HIV/STI Prevention Package For South African Adolescent Girls and Young Women	Kate Merrill, United States	#53
Ritonavir Concentrations in Hair Predict Virological Outcomes in HIV-Infected Adolescents With Virological Treatment Failure to Atazanavir/Ritonavir-Based Second-Line Treatment	Tariro Chawana, Zimbabwe	#54
Using Narrative Films to Combat HIV-Related Stigma in Western Kenya: A Pilot Study of Adolescents Living With HIV And Their Caregivers	Brittany Mccoy, United States	#55
Tenofovir, Lamivudine And Dolutegravir (TLD) Among Rural Adolescents in Zimbabwe, A Cautionary Tale	Vinie Kouamou, Zimbabwe	#56
Feasibility and Acceptability of a Peer Youth Led Curriculum to Improve HIV Knowledge in Northern Tanzania: Resilience and Intervention Experience From the Perspective of Peer Leaders	Kalei Hosaka, United States	#57
Trends in HIV Self-Testing Among Adolescent and Youth Populations Across Sub-Saharan Africa	Madison Ethridge, United States	#58



Saturday, 17 July 2021

Times are in Eastern Daylight Time (EDT)

9:00 AM Young Investigator “Meet the Faculty” - Sign up Required
Lynne Mofenson, Elaine Abrams, Mark Cotton, Patricia Flynn, Carlo Giaquinto, Thanyawee Puthanakit, Nadia Sam-Agudu, and Gareth Tudor-Williams

Session 5 Prevention of HIV in Adolescents and Advancing HIV Drug Evaluation in Pregnancy
Chair: Nadia Sam-Agudu

10:00 AM Long-Acting HIV Prevention in Adolescents: Possibilities and Challenges
Mina Hosseinipour, MD, MPH
 University of North Carolina at Chapel Hill School of Medicine / UNC Project Malawi, Malawi

10:15 AM Approaches to Enhance and Accelerate Study of New Drugs for HIV and Coinfections in Pregnancy
Shahin Lockman, MD, MSc
 Harvard T.H. Chan School of Public Health, United States

10:30 AM Discussion

10:55 AM Virtual Coffee Break - Time to Network

Session 6 Oral Abstract Presentations - 3 Parallel Sessions
Chairs: Amy Slogrove, Jorge Pinto, and Patricia Flynn

Prevention of Perinatal Transmission and HIV-Exposed Uninfected Infants
Chair: Amy Slogrove

11:05 AM	More Frequent Viral Load Testing, With Point-Of-Care Tests Has No Impact on Viral Suppression in Postpartum HIV-Positive Women in a Randomized Controlled Trial in 2 Clinics in Johannesburg, South Africa	Lee Fairlie, South Africa	#19
11:13 AM	Usability and Feasibility of an HIV POC Viral Load to Identify Infants at High Risk of MTCT at Birth in Primary Healthcare Clinics in Mozambique	Bindiya Meggi, Mozambique	#20
11:21 AM	Key Clinical and Programmatic Outcomes of HIV-Exposed Infants in the International Epidemiology Databases to Evaluate AIDS Consortium	Andrew Edmonds, United States	#21
11:29 AM	Determinants of HIV-Free Survival in the Era of Lifelong Universal Antiretroviral Therapy (ART): Pooled Analysis of PEAWIL and IMPROVE Studies, Lesotho	Appolinaire Tiam, United States	#22
11:37 AM	Increased Infectious-Cause Hospitalization Among Infants Who Are HIV-Exposed Uninfected Compared to HIV-Unexposed	Kim Anderson, South Africa	#23
11:45 AM	Growth of Children HIV-Exposed and Uninfected in The Context of Lifelong Maternal Antiretroviral Therapy in Malawi	Gabriela Toledo, United Kingdom	#24
11:53 AM	Q & A		



Pediatric Care

Chair: Jorge Pinto

11:05 AM	There is No Substitute for Hard Work(Ing Dolutegravir): Outcomes of Single Drug Substitutions Among CALHIV Shifted to a Dolutegravir Antiretroviral Regimen in Mbeya and Mwanza, Tanzania	Jason Bacha, Tanzania	#25
11:13 AM	Pediatric ARV Optimization in a Real-World Setting: Dolutegravir Transition in Mozambique	Michelle M. Gill, United States	#26
11:21 AM	Co-Trimoxazole Prophylaxis for Children Born to Mothers With HIV: Predicted Impact of Different Strategies on Mortality Up To the Age of Two Years	Colette Smith, United Kingdom	#27
11:29 AM	Risk Factors for Post-Discharge Mortality Following Hospitalization for Severe Acute Malnutrition in Zimbabwe and Zambia	Mutsa Bwakura- Dangarembizi, Zimbabwe	#28
11:37 AM	Estimated Prevalence of Prior HIV Diagnosis Among Children Living With HIV in Eswatini, Lesotho, Malawi, Tanzania, Zambia, and Zimbabwe in the Population HIV Incidence Assessments (PHIA)	Chloe A. Teasdale, United States	#29
11:45 AM	A Costing Analysis of Index-Linked HIV Testing for Children and Adolescents in Zimbabwe	Arthi Vasantharoopan, United Kingdom	#30
11:53 AM	Q & A		

Adolescents

Chair: Patricia Flynn

11:05 AM	Rapid Antiretroviral NNRTI-based Initiation Among Youth Living with HIV Outcomes in the National AIDS Program in Thailand	Sirinya Teeraananchai, Thailand	#31
11:13 AM	Optimizing Antiretroviral Treatment and Viral Suppression for Adolescents and Young People Living with HIV by Implementing Operation Triple Zero (OTZ) in Four States in Nigeria	Franklin Emerenini, Nigeria	#32
11:21 AM	Projecting Life Expectancy for Youth with Non-Perinatally- and Perinatally-Acquired HIV in the United States	Anne Neilan, United States	#33
11:29 AM	Hospitalisation Rates for Youth Living with Perinatally acquired HIV Transitioning to Adult Care	Sarah Johnson, United Kingdom	#34
11:37 AM	Increasing Capacity to Detect Neurocognitive Impairment among Adolescents and Young Adults with Perinatally Acquired HIV in Thailand: Validity of the NeuorScreen Tablet Application	Reuben N. Robbins, United States	#35
11:45 AM	Development of a Transition Readiness Score for Adolescents Living with Perinatally-Acquired HIV and Transitioning to Adult Care	Brian Zaroni, United States	#36
11:53 AM	Q & A		

12:05 PM Virtual Coffee Break - Time to Network



12:15 PM Symposium - ViiV - Children and Challenges they Face... Our Calling: Optimizing Care in Pediatric HIV Treatment

1:00 PM Virtual Coffee Break - Time to Network

Session 7 Debate - Children Should be Prioritized for COVID-19 Vaccine Implementation

Chair: Carlo Giaquinto

1:10 PM **Introduction & Voting**

1:15 PM **Pro** (*children should be prioritized*):
Marieke van der Zalm, MD, MSc, PhD
Desmond Tutu TB Centre, South Africa

1:35 PM **Con** (*children should not be prioritized*):
Natella Rakhmanina, MD, PhD, FAAP, AAHIVS
Children's National Hospital / Elizabeth Glaser Pediatric AIDS Foundation, United States

1:55 PM **Discussion & Voting**

2:15 PM Virtual Coffee Break - Time to Network

Session 8 COVID-19 in Children and Dolutegravir ART Transition in Pediatrics

Chair: Martina Penazzato

2:25 PM **Situation Report: African COVID-19 Pandemic in Children**
Shabir Madhi, MBBCh, FCPaed, PhD
University of the Witwatersrand, South Africa

2:44 PM **Progress – and Lack of Progress - on DTG Transition in Children in Africa**
Peter Elyanu, MBChB, MMed, PhD
Baylor College of Medicine Children's Foundation, Uganda

3:00 PM **Discussion**

Closing

3:15 PM **Young Investigator Best Oral and Poster Awards**

3:25 PM **Closing Words**
Lynne Mofenson, MD
Elizabeth Glaser Pediatric AIDS Foundation, United States
Elaine Abrams, MD
ICAP at Columbia University, United States



Faculty



WORKSHOP CHAIR
**ELAINE ABRAMS,
MD**

ICAP Mailman School of
Public Health, Columbia
University, United States

Elaine Abrams is a Professor of Epidemiology and Pediatrics at Columbia University with over 35 years of experience in the prevention and treatment of HIV infection and associated infectious diseases in pregnant women, children, and their families.

As the Senior Director for Research at ICAP, she leads ICAP's large research agenda and is responsible for the development of technical assistance and service programs for pediatric and perinatal prevention initiatives for ICAP programs in sub-Saharan Africa and Asia. Dr. Abrams served three consecutive terms as Chair of the NIH-funded IMPAACT network HIV treatment scientific committee and currently guides the network scientific agenda as a member of the Senior Leadership Group.

She chaired the WHO consolidated guidelines for the use of antiretroviral drugs since 2015, introducing universal treatment, antiretrovirals for prevention and optimized antiretroviral regimens with dolutegravir. She is also co-chair of the WHO Pediatric Antiretroviral Working Group and is actively involved in the development of policies and protocols for the study of antiretrovirals in children, adolescents, and pregnant and lactating women.

Dr. Abrams' research interests have focused on maternal-child health, mother-to-child HIV transmission, the natural history of pediatric HIV, and optimizing therapies for infants, children, adolescents and pregnant women and breastfeeding women.

No potential conflict of interest



ORGANIZING COMMITTEE
**MARK COTTON,
MD, PhD**

Stellenbosch University /
Tygerberg Children's
Hospital

Mark Cotton is Head of Division of Paediatric Infectious Diseases and Director of the Family Infectious Diseases Clinical Research Unit at Tygerberg Children's Hospital (TCH), Stellenbosch University (SU). He undertook a fellowship in paediatric infectious diseases at University of Colorado between 1991 and 1995.

He is affiliated to the IMPAACT and PENTA networks and has provided technical support for WHO initiatives since 2004 on the HIV Classification for HIV, antiretroviral guidelines and TB-HIV co-infection. He was co-PI and investigator in several clinical trials in children, both on ART strategy (CHER) and isoniazid prophylaxis and also ARV pharmacokinetics in HIV-infected children.

He is the principal investigator for the SU Clinical Trial Unit (SUN-CTU) with special focus on tuberculosis and HIV. He is involved in vaccine studies for TB and RSV and is including a recombinant BCG vaccine. He is interested in clinical infectious diseases, and all aspects of HIV in children and adolescents.

Potential conflict of interest:

ViiV



INVITED SPEAKER

PETER ELYANU, MBChB, MMed, PhD

Baylor College of Medicine
Children Foundation,
Uganda

Peter Elyanu is a pediatrician and epidemiologist and serves as the Director of research at Baylor College of Medicine Children's Foundation Uganda. He also oversees HIV care and treatment program for children and adolescents at the Baylor-Uganda clinical center of excellence in Kampala.

He also heads the global health security program at Baylor-Uganda which supports the COVID-19 response in Uganda including developing and implementing strategies to promote continuity of care for children and adolescent living with HIV during the COVID-19 pandemic.

Dr Elyanu previously led the Pediatric HIV care and treatment program at the Uganda Ministry of Health where he spearheaded national roll out of test and start guidelines for children. He is a member of the pediatric ART technical working group at the Uganda Ministry of Health, and contributes to policies and guidelines for pediatric and adolescent HIV in Uganda.

His research focuses on Pediatric HIV treatment outcomes and HIV exposed infants.

No potential conflict of interest



ORGANIZING COMMITTEE

PATRICIA FLYNN, MD

St Jude Children's Research
Hospital, United States

Pat Flynn is a Member in the Department of Infectious Diseases at SJCRH where she holds the Arthur Ashe Chair in Pediatric AIDS Research. She is also Professor of Pediatrics and Preventive Medicine at the University of Tennessee Health Science Center. She received her medical training at Louisiana State University Medical Center (1981) and completed Pediatric (1984) and Pediatric Infectious Diseases (1987) training at the University of Tennessee/St. Jude Children's Research Hospital/LeBonheur Children's Medical Center joint program.

Dr. Flynn began working in the HIV/AIDS program at St. Jude Children's Research Hospital in 1988. Over the past 30 years, she has had the opportunity to watch the dramatic reductions in the rate of mother to child HIV transmission and the introduction of active medications that extend the life of HIV-infected persons. She has also witnessed the rising new infection rates in the adolescents through high risk behaviors.

The St. Jude HIV clinic provides comprehensive care for over 300 HIV-infected infants, children, and adolescents. Dr. Flynn and the St. Jude clinic participate in the International Maternal Pediatric and Adolescent Clinical Trials Group (IMPAACT) and the Pediatric HIV/AIDS Cohort Study (PHACS).

Potential conflict of interest:

NIH



INVITED SPEAKER
**CAROLINE FOSTER,
MBBS, MRCPCH**

Imperial College London,
United Kingdom

Dr Caroline Foster is a Consultant in Adolescent HIV and Infectious Diseases at Imperial College Healthcare NHS Trust and is the clinical lead for transitional care in HIV.

Current research studies include, the long term outcomes for adults born with HIV and the characterisation of the latent reservoir.

Research/education/guideline development and lecturing includes BHIVA, CHIVA, HYPNET, CHIPS, AALPHI, PENTA, EPIICAL and UNICEF.

No potential conflict of interest



ORGANIZING COMMITTEE
**CARLO GIAQUINTO,
MD**

PENTA / University of
Padova, Italy

Carlo Giaquinto graduated in Medicine (1982) and specialised in Pediatrics (1986) at the University of Padova. He is Professor at the Department for Woman's and Child's Health of the University of Padova, Director of the Paediatric and Neonatal Infectious Disease Unit at same Department and Director of the Course in Developmental Medicine and Health Planning Sciences at the University of Padova. Prof. Giaquinto is also the President of Fondazione Penta and of Fondazione C.A.R.A.P. Onlus and Scientific Responsible and Vice President of Fondazione Moschino.

His main interest has always been the research in the field of Paediatric Infections and was founder of the European Collaborative Study on the natural history of HIV infections in childhood. He is the coordinator of several International research projects and scientific reviewer of several international journals including The Lancet, AIDS, PIDJ, HIV Medicine, Paediatrics, and Member of the Editorial Board of the research journal "Infectious Diseases" and of "Journal of Virus Eradication".

He is Author/co-author of more than 230 publications published in peer-reviewed and invited as speaker at about 600 conferences and international workshops across the world. On 26th May 2017 Carlo Giaquinto was given the European Society for Paediatric Infectious Diseases (ESPID) Bill Marshal Award.

Potential conflict of interest:
Gilead, ViiV, and J&J



INVITED SPEAKER

**MINA HOSSEINIPOUR,
MD, MPH**

University of North Carolina at Chapel Hill School of Medicine / UNC Project Malawi, Malawi

Mina HosseiniPour is an infectious disease physician and epidemiologist who has lived and worked in Malawi since 2001. She is a Professor of Medicine at UNC-CH, the Scientific director of the UNCPM, and the Co-Principal investigator of the DAIDS sponsored UNC Global Clinical Trials Unit.

She is the Principal Investigator for three NIH funded implementation science capacity building grants and is the co-Chair of the HPTN 084 study evaluating Cabotegravir LA for HIV prevention in women. Her research over the years has encompassed treatment of HIV and its complications, HIV prevention and PMTCT.

She has collaborated with and mentored junior investigators in the evaluation of partner involvement in PMTCT, engagement in care of female sex workers, and evaluation of care delivery services for AGYW.

No potential conflict of interest



INVITED SPEAKER

**KATHERINE HSU,
MD, MPH, FAAP**

Boston University School of Medicine, United States

Katherine Hsu is the Medical Director for the Division of STD Prevention & HIV/AIDS Surveillance, Massachusetts Department of Public Health, and the Director of the Ratelle STD/HIV Prevention Training Center, one of eight STD clinical training centers funded by the Centers for Disease Control and Prevention. She is also an Associate Professor of Pediatrics at Boston University Medical School and Attending Physician in Pediatric Infectious Diseases at Boston University Medical Center. Dr. Hsu graduated from Brown University School of Medicine in 1995, completed pediatric residency at Columbia-Presbyterian Medical Center in 1998, and completed fellowship in Pediatric Infectious Diseases at the Boston University Medical Center in 2001. She also completed a second STD Prevention Fellowship jointly sponsored by the Association of Teachers of Preventive Medicine and the Centers for Disease Control and Prevention in 2003, and received her Masters in Public Health in Epidemiology from the Boston University School of Public Health in 2005.

She was a recipient of the Massachusetts Infectious Disease Society's Edward H. Kass Award for Clinical Excellence During Fellowship in 2001. She is board certified in the areas of Pediatrics and Pediatrics Infectious Diseases, and is a Fellow of American Academy of Pediatrics.

Dr. Hsu's research interests include vaccine-preventable diseases and prevention of sexually transmitted infections, and she has published in various scientific journals, including Vaccine, Archives of Pediatrics and Adolescent Medicine, Pediatric Infectious Disease Journal, Clinical Infectious Diseases, Sexually Transmitted Diseases, and Sexually Transmitted Infections.

No potential conflict of interest



INVITED SPEAKER

**SHAHIN LOCKMAN,
MD, MSc**

Harvard T.H. Chan School of
Public Health, United States

Shanin Lockman is an infectious-disease trained clinician and has conducted clinical trials, epidemiologic and implementation science investigation related to HIV-1 in Botswana since 1996.

One of her research focus areas is the safety and efficacy of antiretroviral drugs used for HIV treatment and prevention among pregnant and postpartum women; she serves as co-chair for the IMPAACT 2010 trial which evaluated the safety and efficacy of DTG- vs. EFV-based antiretroviral treatment regimens in pregnant and postpartum women.

Dr. Lockman also conducts research on health and neurodevelopmental outcomes in HIV-exposed/uninfected children and on community-based HIV prevention, and mentors more than 20 early stage investigators on a range of clinical research projects in Botswana.

She is co-PI of the Botswana Clinical Trials Unit at the Botswana Harvard AIDS Institute Partnership (conducting ACTG, IMPAACT, and HPTN network trials).

No potential conflict of interest



INVITED SPEAKER

**SHABIR MADHI,
MBBCH, FCPAEDS,
PHD**

University of the
Witwatersrand, South Africa

Shabir Madhi is the Dean of the Faculty of Health Sciences and Professor of Vaccinology at the University of the Witwatersrand, Johannesburg, South Africa. He also holds the position of Director of the South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit (VIDA) and is co-Director of the African Leadership Initiative for Vaccinology Expertise (ALIVE).

He has in the past led studies on pneumococcal conjugate vaccine and rotavirus vaccine in Africa, which informed WHO recommendations on the use of these vaccines in low and middle income settings. He has led studies on the clinical development of vaccines for pregnant women aimed at protection of mother-infant dyads against influenza virus, Group B streptococcus and respiratory syncytial virus.

Most recently he led the first two COVID-19 vaccine studies being undertaken in Africa, and has been involved in multiple epidemiological studies on Covid-19 in South Africa. He has co-authored more than 480 scientific manuscripts since 1997, mainly on vaccine preventable diseases.

Potential conflict of interest:

Bill & Melinda Gates Foundation, South African Medical Research Council, and Novavax



INVITED SPEAKER

**MARY MAHY,
ScD, MHSc**

UNAIDS,
Switzerland

Mary Mahy leads the epidemiology team at the Joint United Nations Programme on HIV/AIDS (UNAIDS) where she oversees the production and analysis of global data on the HIV epidemic, including supporting countries to produce annual HIV estimates. Mary also co-facilitates the HIV pediatrics estimates reference group that is linked to the UNAIDS Reference Group on Estimates, Modeling and Projections. Mary is an author on over 30 journal articles on HIV related topics, with a special focus on vertical HIV transmission and estimating child and adolescent HIV.

Prior to moving to UNAIDS headquarters in Geneva, Mary was the UNAIDS strategic information adviser in Namibia where she supported the Namibian Ministry of Health and Social Services to use data to strengthen the HIV response. Before joining UNAIDS Mary was responsible for global monitoring and evaluation of HIV at UNICEF headquarters in New York. She also worked as a research analyst for the Demographic and Health Surveys at Macro International. Mary is a demographer and received her doctorate in population dynamics from the Johns Hopkins School of Hygiene and Public Health. Her dissertation research focused on child mortality and HIV in Zimbabwe.

No potential conflict of interest



WORKSHOP CHAIR

**LYNNE MOFENSON,
MD**

Elizabeth Glaser Paediatric
AIDS Foundation,
United States

Mofenson is a pediatric infectious disease specialist who has spent her career doing research on prevention and treatment of pediatric and maternal HIV infection. In 2014, she retired from the U.S. National Institutes of Health after 26 years, where she led many of the key clinical trials on prevention of mother to child transmission and pediatric and maternal treatment.

She currently serves as Senior HIV Technical Advisor to the Research Program at the Elizabeth Glaser Pediatric AIDS Foundation, where she is assisting in evaluating implementation of many of the interventions on treatment and prevention that she helped to design while at NIH.

No potential conflict of interest



INVITED SPEAKER
**SHARON NACHMAN,
MD**
SUNY Stony Brook /
IMPAACT Network,
United States

Professor Nachman is a scientist and pediatric clinical investigator with more than 25 years of continuous NIH support (U mechanism from the IMPAACT network) dedicated to developing and implementing clinical therapeutic trials for infants, children, adolescents and pregnant women.

She has had leadership roles in over 25 clinical trials developed through the PACTG and now IMPAACT network, including 20 as either protocol chair or vice chair. All studies have enrolled, analyzed, and published results that have changed the way we evaluate and treat HIV infected and exposed children and women worldwide.

While much of her work has centered around these populations, she also developed studies helping to define the dose and PK for new antibiotics, evaluate new vaccines and understand the long term issues that develop in infants born to HIV+ women worldwide. Professor Nachman serves as the PI and Chair of the IMPAACT Network

No potential conflict of interest



INVITED SPEAKER
**MARTINA PENAZZATO,
MD, MSc, PhD**
WHO,
Switzerland

Martina Penazzato is the paediatric lead for the HIV, Hepatitis and STIs Department of WHO Headquarter in Geneva. In her work for the WHO, in addition to providing a major contribution to several Guidelines development processes in the areas of HIV, TB and child health, she has set up surveillance projects to assess HIVDR in HIV-infected infants and provided technical assistance to several countries in the African region.

In her current role she leads the work of WHO on paediatric treatment and care and contributes to a number of global initiatives to improve access to better medicines for children as well as pregnant and lactating women.

No potential conflict of interest



ORGANIZING COMMITTEE
**THANYAWEE PUTHANAKIT,
MD**

Chulalongkorn University,
Thailand

Thanyawee Puthanakit is a pediatric infectious disease specialist at Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. She is a former trainee of the Johns Hopkins University Fogarty AIDS International Training and Research Program.

She started her clinical research in pediatric HIV/AIDS focusing on opportunistic infections and antiretroviral therapy in resource limited settings at Research Institute of Health Sciences, Chiang Mai University in 2002. She is a leader in pediatric HIV treatment and care in Asia.

She leads several multicenter research projects in Thailand, Cambodia, Indonesia and also collaborates with TREAT Asia research program.

She has served on the writing committee for the WHO's pediatric HIV treatment guideline and Thai National Guideline. Her research interest in pediatric and adolescent HIV include antiretroviral therapy and elimination of perinatal HIV transmission and reduction in new cases of adolescent infection.

She conducted a pilot national program using integrase inhibitors intensification regimen for late-presenting pregnant women.

Potential conflict of interest:
ViiV and MSD



INVITED SPEAKER
**NATELLA RAKHMANINA,
MD, PhD, FAAP, FCP,
AAHIVS**

Children's National Hospital
/ EGPAF, United States

Natella Rakhmanina is a Professor of Pediatrics at the George Washington University and serves as a Director of the HIV Program at Children's National Hospital in Washington, DC, USA. Dr. Rakhmanina obtained her MD degree at People's Friendship University in Moscow, Russia, and her PhD degree at the Erasmus University in Rotterdam, the Netherlands.

For more than 20 years she has been providing clinical care to HIV-infected infants, children and adolescents, and continues her practice treating pediatric and adolescent patients in metropolitan DC area. She is certified in HIV medicine and is a successful clinical researcher, focusing her research on the treatment and prevention of HIV in children and adolescents and serving as a principal investigator of NIH, CDC and industry funded pediatric and adolescent HIV studies.

Dr. Rakhmanina is also a Senior Technical Advisor at Elizabeth Glaser Pediatrics AIDS Foundation leading several projects on pediatric and adolescent HIV treatment in Sub-Saharan African countries. Dr. Rakhmanina is a Chair of the Committee on Pediatric AIDS at the American Academy of Pediatrics, member of the US Department of Health and Human Services Panel on the Pediatric Antiretroviral Therapy and Management Guidelines at the Office of AIDS Research Advisory Council in National Institutes of Health, member of the Pediatric Advisory Working Group at the World Health Organization, and a Regent of the Board and Chair of the Bylaws committee at the American College of Clinical Pharmacology.

No potential conflict of interest



ORGANIZING COMMITTEE
**NADIA A. SAM-AGUDU,
MD, CTROPMED**

University of Maryland
School of Medicine / In-
stitute of Human Virology,
United States / Nigeria

Nadia A. Sam-Agudu is a pediatrician working for the Institute of Human Virology at the University of Maryland School of Medicine, Baltimore, USA, where she is also Associate Professor of Pediatrics in Immunology and Infectious Diseases. She is stationed full-time in Nigeria, where she serves as the Senior Technical Advisor for Pediatric and Adolescent HIV at the Institute of Human Virology Nigeria in Abuja.

Dr. Sam-Agudu graduated from the Mayo Clinic Medical School in 2002, and thereafter completed her training in Pediatrics and Pediatric Infectious Diseases at the University of Minnesota, USA. Her career focuses on the control and elimination of infectious diseases of public health importance among African children, specifically HIV, tuberculosis, and malaria.

Dr. Sam-Agudu has research experience in Ghana, Uganda and particularly in Nigeria, where she has provided technical and policy-making support for HIV programs since 2010. Her research interest is in using implementation science methods to generate evidence for sustainable HIV prevention and control among children and adolescents. To this end, she has to date served as Principal Investigator, Project Director or Mentor for projects supported by the World Health Organization, the US National Institutes of Health, the American Academy of Pediatrics, and the International AIDS Society.

No potential conflict of interest



INVITED SPEAKER
KATIE SIMON, MD

Baylor Children's Clinical
Centre of Excellence,
Malawi

Katie Simon is a pediatrician with over 9 years of experience working in Malawi with Baylor College of Medicine Children's Foundation-Malawi on HIV clinical care and treatment programming.

She has served as the Medical Director for the USAID-funded Tingathe Outreach program since 2014, which currently supports the full cascade of HIV Care and Treatment services in 118 health facilities across seven districts in Malawi.

She plays an active role on the pediatric subcommittee of the Malawi Ministry of Health ART/PMTCT Technical Working Group.

No potential conflict of interest



ORGANIZING COMMITTEE

GARETH TUDOR- WILLIAMS, MD

Imperial College London,
United Kingdom

Gareth Tudor-Williams is a Professor of Paediatric Infectious Diseases at Imperial College London, and Consultant in Paediatric Infectious Diseases at Imperial College Healthcare NHS Trust, St. Mary's Hospital, London.

His interest in paediatric infectious diseases was sparked by two years of working in the Himalayas for Save the Children Fund UK. He has specialised in HIV infection in children since 1989, as a Fellow at Duke University, N. Carolina (with Prof. Cathy Wilfert), and as a Visiting Scientist / Attending Physician at the National Institutes of Health, Bethesda, MD (with Prof. Phil Pizzo). Since 1994, he has helped run a multi-disciplinary service for HIV infected children, young people and their families at St. Mary's Hospital, London.

He was the founding Chair of the Children's HIV Association of the UK and Ireland (CHIVA). He has been involved in international Phase II and III trials relating to paediatric blood-borne virus infections for 30 years.

No potential conflict of interest



INVITED SPEAKER

MARIEKE VAN DER ZALM, MD, MSc, PhD

Desmond Tutu TB Centre,
South Africa

Since her medical training, Dr Zalm had a special interest in paediatric infectious diseases and lung health. Her initial work as an undergraduate student on the role of respiratory viruses in children with cystic fibrosis resulted in her PhD proposal, which investigated the role of respiratory viruses in respiratory illnesses early in life in a large Dutch paediatric birth cohort.

She was awarded a PhD fellowship in the Alexandre Suerman program for her PhD research, which included a 2-year bursary to conduct clinical research leading towards a PhD. Whilst performing her PhD research, she had the opportunity to improve her epidemiological skills by completing a Masters' degree in Clinical Epidemiology at the University of Utrecht.

After completion of her PhD she specialized in becoming a paediatrician. Based on her strong interest to work in sub-Saharan Africa, she completed part of her clinical training in paediatrics at Tygerberg Hospital, Stellenbosch University, South Africa and later also at Red Cross Children's Hospital. During this time, she realized her passion was to improve health care in low- and middle-income countries (LMICs) like South Africa, by performing highly relevant clinical research to address the pressing health care issues experienced in these settings. Her main research aim is to improve lung health outcomes in children with pulmonary tuberculosis and other respiratory infections.

During the COVID pandemic she has been involved in the response of the Paediatric Department of Stellenbosch University including with the development of a COVID research that includes routine care surveillance and a prospective observational cohort of children with and without COVID-19.

No potential conflict of interest




PLATINUM LEVEL



GOLD LEVEL



SILVER LEVEL



BRONZE LEVEL





ENDORSERS

ANOVA
HEALTH INSTITUTE

CHIVA
CHILDREN'S HIV ASSOCIATION



DNDi
Drugs for Neglected Diseases initiative



Erasmus MC
Erasmus Universiteit Leiden Amsterdam

IA-PAC
INTERNATIONAL ASSOCIATION
OF PROVIDERS OF AIDS CARE



NATAP
NATIONAL AIDS TREATMENT
ADVOCACY PROJECT
www.natap.org



Penta
Child Health Research

Right
to care
TREATING HEALTH SERIOUSLY

The PACT

UNAIDS

unicef
for every child

YOUTH
AGAINST
AIDS
AN INITIATIVE BY BHRIFUNDATION



We are pleased to announce that the **14th International workshop on HIV Pediatrics** will be held as a hybrid workshop on 27 and 28 July 2022 in Montreal, Canada.

All attendees of HIV Pediatrics 2021 will get a 25% discount on the applicable registration fee. Make sure to register in time to enjoy the Early Fee. Please send an email to lara@amededu.com to obtain a special discount code!

We hope to see you in Montreal!

Register here: <https://virology.eventsair.com/hiv-pediatrics-2022/registration>

INTERNATIONAL WORKSHOP ON **HIV PEDIATRICS** 2022



MONTREAL, CANADA | 27 - 28 JULY



Gilead's Research Scholars Program in HIV

Each award is funded up to \$130,000 for two years, to be paid in annual installments of up to \$65,000 per year. *

Gilead's Research Scholars Program supports innovative research from emerging investigators around the world to advance scientific knowledge in areas of unmet medical needs and improve the lives of patients everywhere.

The Research Scholars Program for HIV is designed to support support basic and clinical research in the field of HIV.

Applications are reviewed and selected by an independent Scientific Review Committee comprised of internationally recognized experts in basic and clinical research in the field of HIV.



Visit researchscholars.gilead.com/available_portals for complete program and eligibility information.

Junior faculty and early-career scientists from the United States, Canada, Europe, Asia and Australia are eligible to apply.

*Awards are subject to separate terms and conditions.

Date of Prep: June 2021
IHQ-UNB-0158

GILEAD and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies.
© 2021 Gilead Sciences, Inc. All rights reserved.





Toward a Generation Without AIDS: How the New Horizons Collaborative is Transforming Pediatric HIV care

Thursday, 15 July 2021
9:00–10:00 AM EST

On July 15, just before the International AIDS Society Conference, Johnson & Johnson will host an event focused on improving pediatric HIV care in sub-Saharan Africa.

J&J and the Elizabeth Glaser Pediatric AIDS Foundation will share progress made in 11 countries through the New Horizons Collaborative (NHC) — and make exciting announcements regarding the program's future.

Be among the first to learn how NHC will continue to advance access to second- and third-line treatment for some of the world's youngest HIV patients.

RSVP here today

We look forward to seeing you there!

Visit [jnj.com/hiv](https://www.jnj.com/hiv) to learn about our efforts to #MakeHIVhistory and [jnj.com/gph](https://www.jnj.com/gph) to read about our broader work to tackle the world's most significant public health challenges.

Visit pedaids.org to learn more about EGPAF's work to end HIV and AIDS in children, youth and families.

UNTIL
CONFUSION
BECOMES

CLARITY

We won't stop until the day people's choices
and lives aren't limited by HIV.

ViiV Healthcare. Here until HIV and AIDS are not.

Click to visit viivhealthcare.com

#WeWontStop



